/Dr. Mimi Roy
How Mass Spectrometry is Accelerating Rare Disease Research
How Mass Spectrometry is Accelerating Rare Disease Research
27 Feb 2018

Mimi Roy, Senior Director of Analytical Chemistry, BioMarin Pharmaceutical Inc., explores the impact of mass spectrometry on medical research, right from drug discovery to compound characterization, through drug manufacturing. The superior precision of the latest mass spectrometry technology has enabled the team at BioMarin to accelerate research into rare diseases such phenylketonuria, mucopolysaccharidosis, or haemophilia.